Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1987 3
1988 6
1989 8
1990 10
1991 15
1992 21
1993 27
1994 36
1995 35
1996 27
1997 31
1998 39
1999 30
2000 34
2001 37
2002 28
2003 33
2004 41
2005 26
2006 43
2007 46
2008 38
2009 42
2010 41
2011 35
2012 39
2013 55
2014 85
2015 105
2016 144
2017 134
2018 121
2019 90
2020 22
Text availability
Article attribute
Article type
Publication date

Search Results

1,333 results
Results by year
Filters applied: . Clear all
Page 1
Prostate cancer post-treatment follow-up and recurrence evaluation.
May EJ, Viers LD, Viers BR, Kawashima A, Kwon ED, Karnes RJ, Froemming AT. May EJ, et al. Abdom Radiol (NY). 2016 May;41(5):862-76. doi: 10.1007/s00261-015-0562-1. Abdom Radiol (NY). 2016. PMID: 27193788 Review.
Common medications and prostate cancer mortality: a review.
Stopsack KH, Greenberg AJ, Mucci LA. Stopsack KH, et al. World J Urol. 2017 Jun;35(6):875-882. doi: 10.1007/s00345-016-1912-5. Epub 2016 Aug 4. World J Urol. 2017. PMID: 27492013 Review.
Prostate cancer: state of the art imaging and focal treatment.
Woodrum DA, Kawashima A, Gorny KR, Mynderse LA. Woodrum DA, et al. Clin Radiol. 2017 Aug;72(8):665-679. doi: 10.1016/j.crad.2017.02.010. Epub 2017 Apr 3. Clin Radiol. 2017. PMID: 28385253 Review.
Neoadjuvant chemohormonal therapy combined with radical prostatectomy and extended PLND for very high risk locally advanced prostate cancer: A retrospective comparative study.
Pan J, Chi C, Qian H, Zhu Y, Shao X, Sha J, Xu F, Wang Y, Karnes RJ, Dong B, Xue W. Pan J, et al. Urol Oncol. 2019 Dec;37(12):991-998. doi: 10.1016/j.urolonc.2019.07.009. Epub 2019 Aug 27. Urol Oncol. 2019. PMID: 31466813
Improvements in treatment planning calculations motivated by tightening IMRT QA tolerances.
Stambaugh C, Gagneur J, Uejo A, Clouser E, Ezzell G. Stambaugh C, et al. J Appl Clin Med Phys. 2019 Jan;20(1):250-257. doi: 10.1002/acm2.12524. Epub 2018 Dec 31. J Appl Clin Med Phys. 2019. PMID: 30599085 Free PMC article.
Clinical and Novel Biomarkers in the Management of Prostate Cancer.
Sanhueza C, Kohli M. Sanhueza C, et al. Curr Treat Options Oncol. 2018 Feb 8;19(2):8. doi: 10.1007/s11864-018-0527-z. Curr Treat Options Oncol. 2018. PMID: 29423762 Review.
Lineage plasticity-mediated therapy resistance in prostate cancer.
Blee AM, Huang H. Blee AM, et al. Asian J Androl. 2019 May-Jun;21(3):241-248. doi: 10.4103/aja.aja_41_18. Asian J Androl. 2019. PMID: 29900883 Free PMC article. Review.
Targeted prostate biopsy and MR-guided therapy for prostate cancer.
Woodrum DA, Kawashima A, Gorny KR, Mynderse LA. Woodrum DA, et al. Abdom Radiol (NY). 2016 May;41(5):877-88. doi: 10.1007/s00261-016-0681-3. Abdom Radiol (NY). 2016. PMID: 26907717 Free PMC article. Review.
Vitamins and prostate cancer risk.
Donkena KV, Karnes RJ, Young CY. Donkena KV, et al. Molecules. 2010 Mar 12;15(3):1762-83. doi: 10.3390/molecules15031762. Molecules. 2010. PMID: 20336012 Free PMC article. Review.
Single-Nucleotide Polymorphisms Sequencing Identifies Candidate Functional Variants at Prostate Cancer Risk Loci.
Zhang P, Tillmans LS, Thibodeau SN, Wang L. Zhang P, et al. Genes (Basel). 2019 Jul 18;10(7):547. doi: 10.3390/genes10070547. Genes (Basel). 2019. PMID: 31323811 Free PMC article.
1,333 results
Jump to page
Feedback